07:00 , Sep 29, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear receptor binding protein 2 (NRBP2)

Cancer INDICATION: Liver cancer Patient samples and cell culture studies suggest promoting NRBP2 expression could enhance the sensitivity of hepatocellular carcinoma (HCC) to chemotherapy. In tissue samples from HCC patients, levels of NRBP2 were lower...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Company News

Aeterna Zentaris, Merck KGaA sales and marketing update

Aeterna said it will transfer manufacturing rights for in vitro fertilization (IVF) drug Cetrotide cetrorelix acetate to marketing partner Merck Serono S.A. , a division of Merck, in exchange for €2.5 million ($3.3 million). Aeterna...
07:00 , Mar 18, 2013 |  BC Week In Review  |  Clinical News

Perifosine: Development discontinued

Aeterna Zentaris discontinued development of perifosine to treat MM after a pre-planned interim analysis of a double-blind, international Phase III trial by an independent DSMB showed that once-daily 50 mg oral perifosine plus Velcade bortezomib...
07:00 , Mar 18, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biogen Idec Inc. (NASDAQ:BIIB) gained $4.40 to $176.78 last week after submitting a BLA to FDA for rFVIIIFc to treat hemophilia A. The product is partnered with Swedish Orphan Biovitrum AB (SSE:SOBI), which...
00:07 , Mar 12, 2013 |  BC Extra  |  Clinical News

Aeterna falls after perifosine misses in multiple myeloma

Shares of Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) fell on Monday after the company discontinued development of perifosine for multiple myeloma (MM). The move came after interim Phase III data showed perifosine plus Velcade bortezomib and...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer  A strong crop of early PDUFA dates and a sense that FDA is more navigable have given money managers in the U.S. and Europe a positive outlook for 2013, which they...
00:42 , Dec 29, 2012 |  BC Extra  |  Company News

Aeterna up on SPA for Phase III for AEZS-108

Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) gained C$0.33 (15%) to C$2.49 on Friday after it said it reached an agreement with FDA on an SPA for a Phase III trial of AEZS-108 for endometrial cancer. On...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

Perifosine: Final Phase II data

Final data from a Phase II trial in 40 patients with relapsed and/or refractory lymphomas who failed second- or subsequent-line salvage chemotherapy showed that patients who achieved less than a partial response after 4 weeks...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

Perifosine: Phase I data

Perifosine has Orphan Drug designation in the U.S. to treat neuroblastoma. In May, Aeterna and Keryx Biopharmaceuticals Inc. (NASDAQ:KERX, New York, N.Y.) mutually terminated a deal that gave Keryx North American rights to perifosine. Keryx...
01:14 , Oct 13, 2012 |  BC Extra  |  Financial News

Aeterna adds $16.5M in follow-on

Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) raised $16.5 million through the sale of 6.6 million units at $2.50 in a follow-on underwritten by Roth Capital Partners. Each unit comprises a share and a five-year warrant to...